Researchers survey Weight-Loss drug users to understand Real-World experiences
NCT ID NCT07154238
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects information through online surveys from about 2,500 adults in Australia, Germany, UAE, and Spain who have been prescribed injectable semaglutide for weight management. The goal is to understand their characteristics, treatment experiences, and changes in weight and quality of life. No new treatment or lab tests are involved; it is purely a research survey.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novo Nordisk Investigational Site
Bad Oeynhausen, 32545, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?